@SaiParepally yeah pretty much everything - business product mgmt. sort of crazy this is worth $7.5b as a services biz when it is almost definitely a LT zero and pretty much just running on fumes of legacy SW to support it
@ComebackCap the only redeeming qualities are 1) its objectively sort of cheap on a pure multiples basis 2) the business model is innately pretty good so hard to completely f*ck up
@ComebackCap Pat is an idiot and is completely fixated on hitting the quarter. meanwhile pipeline is flat / negative (they keep changing definitions and moving stuff around) and HLT / MAR midscale conversion becoming a material % headwind to units. checks on franchisees are awful
@viggy_krishnan 4) bulls prev negligent - believed CRM can't/wont build "real" product/ compete...but now clear they are serious + further along than most ppl thought 5) while val'n more palatable, risk is margins killed if above happens b/c they will have much worse negotiating dynamic w top 20
@viggy_krishnan think its a mix. slate of issues currently are 1) R&D decel'ing 2) commercial growth is a ? bc add-on modules havent worked, pushing needle too far on price, issues ex-CRM bc pharma reps in decline 3) lost key talent to CRM who is ahead in AI & likely better relationship wrt IQV